ArticleJournal of neuro-oncology2025
Hormonal factors predisposing to the development of meningiomas in men: a case-control study.
Article in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe characterization of meningiomas within the male population, particularly regarding the potential over-representation of hormonal factors, currently lacks precision, emphasizing the need for a comprehensive understanding of risk factors influencing their development or growth. This study aims to delineate the hormonal profiles in males diagnosed with meningiomas and seeks to identify whether specific factors are more prevalent in this population compared to a control group.
methodsA case-control study was conducted, involving eligible individuals (n = 288) diagnosed with intracranial meningiomas between January 1st, 2003, and January 1st, 2021, at ‘Hôpital de l’Enfant-Jésus CHU-de-Québec – Université Laval’. Hormonal exposure, including 5α-reductase inhibitors, gonadotropin-releasing hormone (GnRH), testosterone, anti-androgens, medication for alopecia and hair loss, spironolactone, and other hormonal comorbidities, was assessed.
resultsA statistically significant association was identified between the use of 5α-reductase inhibitors and an increased risk of meningioma in men (OR 5.99 [1.99–18.06], p = 0.0015). Vasectomy (OR 0.35 [0.18–0.68], p = 0.0021) and alopecia (OR 0.24 [0.12–0.45], p = < 0.0001) were associated with a decreased risk of meningioma, while other endogenous and exogenous hormonal factors showed no significant associations with meningioma development.
conclusionThe study highlights a potential link between 5α-reductase inhibitor use and meningioma development, suggesting a role for progesterone in the pathophysiology. While the findings related to vasectomy and alopecia warrant further investigation, they are likely limited by study design biases. These results emphasize the need for more robust, prospective studies to better understand the hormonal factors influencing meningioma risk.
Indexed as
Identifiers
41171375What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.